![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 16, 2017 9:54:08 PM
Go to Biogen website>Investor Relations>Presentations.
They have another one tomorrow regarding early detection of ALZ, understandable since the current study is Prodromal and Mild cases of ALZ.
See how the market reacts to both Biogen and Anavex on Monday.
If the market likes this presentation then Technically BIIB has mapped out an almost perfect cup and handle formation (late April to NOW) already and all would be sitting right at the break-out trigger point. This could be a HUGE gainer over the next few days IF the Market likes this Presentation at AAIC. However, just as likely to see a drop on the good ole Biotech "Sell the News' reaction.
Recent BIIB News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:30:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:55:02 AM
- Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen • PR Newswire (US) • 07/31/2024 01:00:00 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC • GlobeNewswire Inc. • 07/30/2024 09:15:17 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20 • PR Newswire (US) • 07/30/2024 09:00:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union • GlobeNewswire Inc. • 07/26/2024 11:20:38 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB • PR Newswire (US) • 07/16/2024 08:00:00 AM
- Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB • PR Newswire (US) • 07/12/2024 09:45:00 AM
- July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Biogen Completes Acquisition of Human Immunology Biosciences • GlobeNewswire Inc. • 07/02/2024 01:16:51 PM
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
- Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/17/2024 09:45:00 AM
- Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/10/2024 09:45:00 AM
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease • GlobeNewswire Inc. • 06/09/2024 11:37:43 PM
- FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease • PR Newswire (US) • 06/09/2024 11:30:00 PM
- Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM